Press Releases

Date Title and Summary
Toggle Summary Accuray Generated $55.6 Million in First Quarter Gross Orders; Revenue Increased 5 Percent Year over Year
SUNNYVALE, Calif. , Oct. 24, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first fiscal quarter ended September 30, 2017 . First Quarter Highlights Gross orders increased 11 percent to $55.6 million , net orders were $51.0 million .
Toggle Summary European Court of Appeal Rejects Varian's Attempt to Reverse Customer Purchase of Accuray TomoTherapy® System
SUNNYVALE, Calif. , Oct. 19, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accuray TomoTherapy® System by University Hospital of Tours (CHU).
Toggle Summary Accuray To Report Fiscal 2018 First Quarter Financial Results On October 24, 2017
SUNNYVALE, Calif. , Oct. 10, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2017 on Tuesday, October 24, 2017 after the market close.  Management will host a conference call to review the results at 1:30 p.m. PT / 4:30 p.m.
Toggle Summary Accuray Incorporated Reports Inducement Grant Under NASDAQ Listing Rules
SUNNYVALE, Calif. , Oct. 4, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, an equity inducement award to Shig Hamamatsu , the company's new VP, Finance & Chief Accounting Officer. As a material inducement to Mr.
Toggle Summary 10-year Data Shows CyberKnife® System Provides Excellent Long-term Control of Low-Risk Prostate Cancer
First Study to Evaluate the Use of Stereotactic Body Radiation Therapy in Low-Risk Prostate Cancer 10 Years Post Treatment SUNNYVALE, Calif. , Sept. 26, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective study of 230 men with low-risk prostate
Toggle Summary Accuray Showcases CyberKnife® and Radixact™ Systems at ASTRO 2017
SUNNYVALE, Calif. , Sept. 20, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that data and first-hand experience with its advanced CyberKnife® and Radixact™ Systems , and unique software solutions, will be shared by leading radiation oncology practitioners at the 2017
Toggle Summary Accuray Reports Fourth Quarter and Fiscal 2017 Financial Results
SUNNYVALE, Calif. , Aug. 22, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2017 . Q4 Fiscal 2017 and Recent Highlights Gross orders of $85.7 million driven by strong demand from both the new Radixact
Toggle Summary Summit Cancer Center-Boise Treats Its First Cancer Patients Using the Accuray Radixact™ System
Freestanding Center is First in the Western U.S. to Treat Patients with this "Smart" Radiation Therapy Delivery System with Fully-Integrated Treatment Planning and Data Management Systems SUNNYVALE, Calif. , Aug. 17, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) and the Summit Cancer
Toggle Summary Accuray To Report Fiscal 2017 Fourth Quarter And Full Year Results On August 22, 2017
SUNNYVALE, Calif. , Aug. 14, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2017 ended June 30, 2017 on Tuesday, August 22, 2017 after the market close. Management will host a conference call to review the results at 1:30 p.m.
Toggle Summary First Radixact™ System Research Results Presented at the American Association of Physicists in Medicine Annual Meeting
SUNNYVALE, Calif. , Aug. 4, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that the first studies validating the benefits of the leading-edge Radixact™ System were presented at the 59th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in